Cellular immunotherapy in multiple myeloma
In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendri...
Saved in:
| Published in | The Korean journal of internal medicine Vol. 34; no. 5; pp. 954 - 965 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Association of Internal Medicine
01.09.2019
대한내과학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1226-3303 2005-6648 2005-6648 |
| DOI | 10.3904/kjim.2018.325 |
Cover
| Abstract | In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects. |
|---|---|
| AbstractList | In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects. In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects. KCI Citation Count: 0 In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects.In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth and survival. Tremendous improvements have been made in the treatment of MM over the past decade but cellular immunotherapy using dendritic cells, natural killer cells, and genetically engineered T-cells represent a new therapeutic era. The application of these treatments is growing rapidly, based on their capacity to eradicate MM. In this review, we summarize recent progress in cellular immunotherapy for MM and its future prospects. |
| Author | Park, Hye-Seong Kim, Hyeoung-Joon Jung, Sung-Hoon Lee, Hyun-Ju Cho, Duck Lee, Je-Jung Chu, Tan-Huy Vo, Manh-Cuong Lakshmi, Thangaraj Jaya Kim, Sang-Ki |
| Author_xml | – sequence: 1 givenname: Manh-Cuong surname: Vo fullname: Vo, Manh-Cuong – sequence: 2 givenname: Thangaraj Jaya surname: Lakshmi fullname: Lakshmi, Thangaraj Jaya – sequence: 3 givenname: Sung-Hoon surname: Jung fullname: Jung, Sung-Hoon – sequence: 4 givenname: Duck surname: Cho fullname: Cho, Duck – sequence: 5 givenname: Hye-Seong surname: Park fullname: Park, Hye-Seong – sequence: 6 givenname: Tan-Huy surname: Chu fullname: Chu, Tan-Huy – sequence: 7 givenname: Hyun-Ju surname: Lee fullname: Lee, Hyun-Ju – sequence: 8 givenname: Hyeoung-Joon surname: Kim fullname: Kim, Hyeoung-Joon – sequence: 9 givenname: Sang-Ki surname: Kim fullname: Kim, Sang-Ki – sequence: 10 givenname: Je-Jung surname: Lee fullname: Lee, Je-Jung |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30754964$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002494305$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNp9UVuL1DAUDrLizq4--irzqELHk0vT5EVYBi8DC4Ksz-GkTXczkzZj2irz781M18UV9OlA8l3O950LctbH3hHyksKKaxDvdlvfrRhQteKsfEIWDKAspBTqjCwoY7LgHPg5uRiGLYCsQPFn5JxDVQotxYK8XbsQpoBp6btu6uN45xLuD0vfL7spjH4f3LI7uBA7fE6ethgG9-J-XpJvHz_crD8X118-bdZX10UtVDUWzkqK1CKVCNbZRqOExmnGoLXYCqs1dUA5tlY7gQ2trLbcQSMaTVXZUH5J3sy6fWrNrvYmoj_N22h2yVx9vdmYUleSV5CxmxnbRNyaffIdpsOJcHqI6dZgGn0dnHGgFZMKQOR2mlprUKqGhgkrq5YjZq3VrDX1ezz8xBAeBCmYY9nmWLY5lm1y2ZnwfibsJ9u5pnb9mDA82uLxT-_vcogfRlZUVUJlgdf3Ail-n9wwms4PdT4I9i5Og2GMaci-Wmboqz-9Hkx-XzID-AyoUxyG5FpT-xFHH4_WPvwzQvEX6_-RfwESmcEy |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2024_e27892 crossref_primary_10_1016_j_lfs_2020_118209 crossref_primary_10_1016_j_jcyt_2022_05_004 crossref_primary_10_1021_acs_jproteome_1c00007 crossref_primary_10_1016_j_tranon_2022_101413 crossref_primary_10_1016_j_jcyt_2023_11_002 crossref_primary_10_1007_s00262_020_02654_0 |
| Cites_doi | 10.3389/fimmu.2018.01798 10.1016/j.jocit.2014.11.001 10.1016/S0140-6736(04)15736-X 10.2217/imt.11.102 10.1080/2162402X.2018.1472187 10.1007/s13238-016-0367-1 10.1083/jcb.124.1.71 10.18632/oncotarget.5281 10.1097/CJI.0000000000000097 10.3390/ijms17091506 10.1016/j.smim.2016.03.002 10.1038/leu.2009.236 10.1038/nm.3910 10.3389/fimmu.2015.00578 10.1046/j.1365-2141.2002.03879.x 10.1080/2162402X.2016.1250051 10.1056/NEJMra041875 10.18632/oncotarget.15917 10.3389/fimmu.2013.00363 10.1016/j.ymthe.2018.03.016 10.1016/j.ymthe.2017.04.024 10.3389/fphar.2015.00021 10.1038/nrclinonc.2013.46 10.1038/bcj.2015.32 10.1155/2015/706379 10.4068/cmj.2015.51.1.1 10.1016/j.exphem.2016.11.004 10.4049/jimmunol.1002460 10.1200/JCO.2017.35.15_suppl.LBA3001 10.1007/s12185-018-2405-7 10.1016/S1083-8791(00)70027-9 10.1038/bmt.2012.1 10.1053/j.seminhematol.2008.09.004 10.1097/CJI.0b013e31821ca6ce 10.1038/leu.2013.279 10.1172/JCI86000 10.1158/2159-8290.CD-12-0548 10.1371/journal.pone.0076781 10.3389/fimmu.2018.01370 10.1016/j.ccell.2015.09.004 10.1007/s00018-016-2135-z 10.18632/oncotarget.17517 10.1016/j.jcyt.2015.06.002 10.1097/CJI.0000000000000059 10.1182/blood-2005-05-2177 10.3904/kjim.2015.408 10.1038/emm.2016.69 10.1007/s13238-017-0415-5 10.1111/j.1365-2141.2009.07649.x 10.1182/blood-2014-12-580068 10.1111/bjh.14570 10.3324/haematol.2011.056747 10.1053/j.seminhematol.2009.02.006 10.1182/blood-2017-06-793869 10.1200/JCO.2018.36.15_suppl.8007 10.1158/0008-5472.CAN-07-3096 10.1182/blood-2016-08-731885 10.1182/blood.V100.1.230 10.1172/jci.insight.120505 10.1038/jid.2011.36 10.1016/B978-0-12-800267-4.00003-1 10.1016/j.cell.2017.01.016 10.1016/j.critrevonc.2017.01.011 10.1016/j.exphem.2013.12.008 10.1007/978-1-4939-0345-0_2 10.3389/fimmu.2017.00892 |
| ContentType | Journal Article |
| Copyright | Copyright © 2019 The Korean Association of Internal Medicine 2019 |
| Copyright_xml | – notice: Copyright © 2019 The Korean Association of Internal Medicine 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTOC UNPAY DOA ACYCR |
| DOI | 10.3904/kjim.2018.325 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals Korean Citation Index |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals (DOAJ) url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2005-6648 |
| EndPage | 965 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_5976370 oai_doaj_org_article_e098268004664dc99088c0d24b67f3aa 10.3904/kjim.2018.325 PMC6718748 30754964 10_3904_kjim_2018_325 |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: National Research Foundation of Korea grantid: 2018R1C1B5041536 – fundername: National Research Foundation of Korea grantid: 2018R1A5A2024181 |
| GroupedDBID | --- 123 29L 85H 8XY 9ZL AAYXX ACYCR ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK DU5 E3Z F5P FRP GROUPED_DOAJ GX1 HYE HZB KQ8 M48 OK1 PGMZT RPM ADRAZ CGR CUY CVF ECM EIF MZR M~E NPM ZXP ZZE 7X8 5PM ADTOC UNPAY |
| ID | FETCH-LOGICAL-c487t-eb61a1ba16a0bebd9a60de9220fbaf4b991e013afb9e4ad17b9b3e0d4d9185d13 |
| IEDL.DBID | M48 |
| ISSN | 1226-3303 2005-6648 |
| IngestDate | Tue Nov 21 21:36:05 EST 2023 Fri Oct 03 12:50:56 EDT 2025 Sun Oct 26 04:11:34 EDT 2025 Tue Sep 30 16:53:50 EDT 2025 Wed Oct 01 14:31:13 EDT 2025 Thu Jan 02 22:59:10 EST 2025 Thu Apr 24 23:12:06 EDT 2025 Wed Oct 01 03:31:46 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | Killer cells, natural Cellular immunotherapy Dendritic cells Engineered effector T cell Immunomodulatory drug Multiple myeloma |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. cc-by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c487t-eb61a1ba16a0bebd9a60de9220fbaf4b991e013afb9e4ad17b9b3e0d4d9185d13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 These authors contributed equally to this work. |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=http://www.kjim.org/upload/kjim-2018-325.pdf |
| PMID | 30754964 |
| PQID | 2229090496 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_5976370 doaj_primary_oai_doaj_org_article_e098268004664dc99088c0d24b67f3aa unpaywall_primary_10_3904_kjim_2018_325 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6718748 proquest_miscellaneous_2229090496 pubmed_primary_30754964 crossref_citationtrail_10_3904_kjim_2018_325 crossref_primary_10_3904_kjim_2018_325 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-09-01 |
| PublicationDateYYYYMMDD | 2019-09-01 |
| PublicationDate_xml | – month: 09 year: 2019 text: 2019-09-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | The Korean journal of internal medicine |
| PublicationTitleAlternate | Korean J Intern Med |
| PublicationYear | 2019 |
| Publisher | The Korean Association of Internal Medicine 대한내과학회 |
| Publisher_xml | – name: The Korean Association of Internal Medicine – name: 대한내과학회 |
| References | ref13 ref57 ref12 ref56 ref15 ref59 ref14 ref58 ref53 ref52 ref11 ref55 ref10 Harada (ref45) 1993 ref17 ref16 ref19 ref18 Cohen (ref51) 2017 ref50 ref48 ref47 ref42 ref41 ref44 ref43 ref49 ref8 ref7 ref9 ref4 ref3 ref6 ref5 ref40 ref35 Jung (ref28) 2017 ref34 ref37 ref36 ref31 ref30 ref33 ref32 ref2 ref1 ref39 ref38 Yan (ref54) 2017 ref71 ref70 ref72 Podar (ref46) 2010 ref24 ref68 ref23 ref67 ref26 ref25 ref69 ref20 ref64 ref63 ref22 ref66 ref21 ref65 ref27 ref29 ref60 ref62 ref61 |
| References_xml | – ident: ref31 doi: 10.3389/fimmu.2018.01798 – ident: ref47 doi: 10.1016/j.jocit.2014.11.001 – ident: ref1 doi: 10.1016/S0140-6736(04)15736-X – ident: ref59 doi: 10.2217/imt.11.102 – ident: ref17 doi: 10.1080/2162402X.2018.1472187 – ident: ref55 doi: 10.1007/s13238-016-0367-1 – ident: ref41 doi: 10.1083/jcb.124.1.71 – ident: ref27 doi: 10.18632/oncotarget.5281 – ident: ref30 doi: 10.1097/CJI.0000000000000097 – ident: ref14 doi: 10.3390/ijms17091506 – ident: ref57 doi: 10.1016/j.smim.2016.03.002 – ident: ref11 doi: 10.1038/leu.2009.236 – ident: ref58 doi: 10.1038/nm.3910 – ident: ref60 doi: 10.3389/fimmu.2015.00578 – ident: ref63 doi: 10.1046/j.1365-2141.2002.03879.x – ident: ref68 doi: 10.1080/2162402X.2016.1250051 – ident: ref2 doi: 10.1056/NEJMra041875 – ident: ref12 doi: 10.18632/oncotarget.15917 – ident: ref56 doi: 10.3389/fimmu.2013.00363 – ident: ref52 doi: 10.1016/j.ymthe.2018.03.016 – ident: ref44 doi: 10.1016/j.ymthe.2017.04.024 – ident: ref71 doi: 10.3389/fphar.2015.00021 – ident: ref34 doi: 10.1038/nrclinonc.2013.46 – ident: ref6 doi: 10.1038/bcj.2015.32 – ident: ref24 doi: 10.1155/2015/706379 – ident: ref23 doi: 10.4068/cmj.2015.51.1.1 – ident: ref19 doi: 10.1016/j.exphem.2016.11.004 – ident: ref29 doi: 10.4049/jimmunol.1002460 – ident: ref53 doi: 10.1200/JCO.2017.35.15_suppl.LBA3001 – ident: ref62 doi: 10.1007/s12185-018-2405-7 – ident: ref20 doi: 10.1016/S1083-8791(00)70027-9 – ident: ref10 doi: 10.1038/bmt.2012.1 – ident: ref39 – ident: ref7 doi: 10.1053/j.seminhematol.2008.09.004 – ident: ref32 doi: 10.1097/CJI.0b013e31821ca6ce – start-page: 2799 year: 2010 ident: ref46 – ident: ref69 doi: 10.1038/leu.2013.279 – ident: ref35 doi: 10.1172/JCI86000 – ident: ref37 doi: 10.1158/2159-8290.CD-12-0548 – ident: ref65 doi: 10.1371/journal.pone.0076781 – ident: ref33 doi: 10.3389/fimmu.2018.01370 – ident: ref38 doi: 10.1016/j.ccell.2015.09.004 – ident: ref8 doi: 10.1007/s00018-016-2135-z – ident: ref13 doi: 10.18632/oncotarget.17517 – ident: ref22 doi: 10.1016/j.jcyt.2015.06.002 – start-page: 505 volume-title: Safety and efficacy of B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) with cyclophosphamide conditioning for refractory multiple myeloma (MM) year: 2017 ident: ref51 – ident: ref66 doi: 10.1097/CJI.0000000000000059 – start-page: 41538 volume-title: A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma year: 2017 ident: ref28 – ident: ref72 doi: 10.1182/blood-2005-05-2177 – ident: ref3 doi: 10.3904/kjim.2015.408 – ident: ref25 doi: 10.1038/emm.2016.69 – ident: ref70 doi: 10.1007/s13238-017-0415-5 – start-page: 2658 volume-title: Phenotypic difference of normal plasma cells from mature myeloma cells year: 1993 ident: ref45 – ident: ref4 doi: 10.1111/j.1365-2141.2009.07649.x – ident: ref36 doi: 10.1182/blood-2014-12-580068 – ident: ref67 doi: 10.1111/bjh.14570 – ident: ref64 doi: 10.3324/haematol.2011.056747 – ident: ref5 doi: 10.1053/j.seminhematol.2009.02.006 – ident: ref40 doi: 10.1182/blood-2017-06-793869 – ident: ref50 doi: 10.1200/JCO.2018.36.15_suppl.8007 – ident: ref49 doi: 10.1158/0008-5472.CAN-07-3096 – ident: ref15 doi: 10.1182/blood-2016-08-731885 – ident: ref18 doi: 10.1182/blood.V100.1.230 – ident: ref48 doi: 10.1172/jci.insight.120505 – start-page: 506 volume-title: Combined infusion of CD19 and Bcma-specific chimeric antigen receptor T cells for RRMM: initial safety and efficacy report from a clinical pilot study year: 2017 ident: ref54 – ident: ref42 doi: 10.1038/jid.2011.36 – ident: ref61 doi: 10.1016/B978-0-12-800267-4.00003-1 – ident: ref9 doi: 10.1016/j.cell.2017.01.016 – ident: ref16 doi: 10.1016/j.critrevonc.2017.01.011 – ident: ref21 doi: 10.1016/j.exphem.2013.12.008 – ident: ref26 doi: 10.1007/978-1-4939-0345-0_2 – ident: ref43 doi: 10.3389/fimmu.2017.00892 |
| SSID | ssj0067083 |
| Score | 2.2183542 |
| SecondaryResourceType | review_article |
| Snippet | In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor's escape from immune surveillance and, therefore, its growth... In multiple myeloma (MM), the impaired function of several types of immune cells favors the tumor’s escape from immune surveillance and, therefore, its growth... |
| SourceID | nrf doaj unpaywall pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 954 |
| SubjectTerms | Animals Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Cancer Vaccines - adverse effects Cancer Vaccines - therapeutic use cellular immunotherapy dendritic cells Dendritic Cells - immunology Dendritic Cells - transplantation engineered effector t cell Humans immunomodulatory drug Immunotherapy, Adoptive - adverse effects killer cells, natural Killer Cells, Natural - immunology Killer Cells, Natural - transplantation multiple myeloma Multiple Myeloma - genetics Multiple Myeloma - immunology Multiple Myeloma - pathology Multiple Myeloma - therapy Receptors, Chimeric Antigen - genetics Receptors, Chimeric Antigen - immunology Review T-Lymphocytes - immunology T-Lymphocytes - transplantation Treatment Outcome 내과학 |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD8AF8U1KQQEhkBChduza8REqqoJUTlTqzRrHNk03zVbLrtD--84k2dWu-LpwipQ4kfMmzsyTZ94w9irJylShSpRWzgsVIBZWB1uApGaF9UGpDNU7n3zVx6fqy9nB2UarL8oJG-SBB-D2I7cYAVfE47QKtaW8nJqHUnltkoQ-NOKVXZGp4R-sDe8FOAUGFwUydjmoayK_V_uTi4Yq0EX1XlJ_7A1v1Iv2o4_pZul38eavaZO3Ft0VLH9C2274pKO77M4YTOYfhpe4x27E7j67eTJulz9gbw9j21Kead5QGchYbLXMmy5fJRLml8vYTi_hITs9-vTt8LgYmyMUNXKMeRG9FiA8CA3cRx8saB6iLUuePCTlMe6LGN5B8jYqCMJ462XkQQWLLjoI-YjtdNMuPmF5HTkALm5hoVSRG0B0FaQSkkTuXIuMvVuB5OpROZwaWLQOGQRh6ghTR5g6xDRjr9fDrwbJjD8N_EiIrweR0nV_Au3vRvu7f9k_Yy_RXm5SN_39dPw-dZOZQz7w2SFd0tLwjL1YmdPh8qE9EejidPHDUTtzjjOzOmOPB_Ou54O_P2TPWmXMbBl-a8LbV7rmvJfo1oZ6HVYZe7P-RP6Oxe7_wOIpu43PG1Pg9tjOfLaIzzBmmvvn_fK4BlNVEcg priority: 102 providerName: Directory of Open Access Journals – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-NTgJe-P4IXwoIgYRI5ySuEz-OiWkgdeKBSuPJOscOdE3TqrRC5a_nLkmrVQO0p3w5kXM-x_fL_e4O4HWZ5lnu8pJp5SKSDn2kldMRplyssBgkMuN45-GpOhnJz2eDsz3YlJJjVuXkfDxtfPireTVDd8DHNJhxHqXJoD935TXYVwOyvHuwPzr9cviNMRVZERFBc3YoN8k1lZJ5m1KTQL1snsE8rryfclHsC0tQk6mfFpZ6Uf7NyLzMlbyxque4_oVVdWEhOr4Nw004T8s_mfRXS9svfl_O7nild7wDtzqLNDxsVegu7Pn6Hlwfdj73-_DuyFcVk1XDMceSdBFb63Bchxs2Yjhd-2o2xQcwOv749egk6iosRAUBlWXkrYoxthgrFNZbp1EJ53WSiNJiKS0Zj55sRCyt9hJdnFltUy-cdJrWeRenD6FXz2r_GMLCC0T6QsQaE-lFho4MBywTLFMC4EUcwPuN0E3RpR_nKhiVIRjCY2RYBoZlYEgGAbzZNp-3eTf-1fADj-C2EafLbk6QdE03-4wXmmBUzj8DlHSFZnJXIaiHVmVlihjAKxp_MynGzf28_T4zk4UhUPHJEOZSaSYCeLlRD0NzkB0rWPvZ6qfhmuiCeqZVAI9addn2h76hBMGVDCDbUaSdDu9eqcc_mjzfKuOCiXkAb7cq939ZPLlyy6dwk3Y7stwz6C0XK_-crKulfdFNqj9agiJq priority: 102 providerName: Unpaywall |
| Title | Cellular immunotherapy in multiple myeloma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30754964 https://www.proquest.com/docview/2229090496 https://pubmed.ncbi.nlm.nih.gov/PMC6718748 http://www.kjim.org/upload/kjim-2018-325.pdf https://doaj.org/article/e098268004664dc99088c0d24b67f3aa https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002494305 |
| UnpaywallVersion | publishedVersion |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | The Korean Journal of Internal Medicine, 2019, 34(5), , pp.954-965 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2005-6648 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067083 issn: 2005-6648 databaseCode: KQ8 dateStart: 19860101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: Directory of Open Access Journals (DOAJ) customDbUrl: eissn: 2005-6648 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067083 issn: 2005-6648 databaseCode: DOA dateStart: 19860101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2005-6648 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067083 issn: 2005-6648 databaseCode: DIK dateStart: 19860101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2005-6648 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067083 issn: 2005-6648 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2005-6648 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067083 issn: 2005-6648 databaseCode: RPM dateStart: 19860101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2005-6648 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0067083 issn: 2005-6648 databaseCode: M48 dateStart: 19860101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED_BJsFeEN-EjyogBBIiw0lcJ35AaExMG6gTD1QaT9Y5dkbWLB1dK-h_z12aFqoNxFOixJas3_ly94vvA-B5meZZ7vKSw8pFJB36SCunI0y5WWHRT2TG-c6DQ7U_lB-P-ke_Swp1AJ5fSu24n9RwUm___D5_Rwr_lhmnFvLN6KTinPI4306T_lXYJCOluYvDQK4OFFQm2oqcMXkbEVH4dFFu8-L0NfPUVvEno9NMyssc0ItxlNdnzRnOf2Bd_2Gk9m7Cjc67DHcW2-EWXPHNbbg26M7P78CrXV_XHHgaVpwX0mVfzcOqCZeRheHp3NfjU7wLw70PX3b3o65bQlQQ6ZhG3qoYY4uxQmG9dRqVcF4niSgtltKSI-jJ38PSai_RxZnVNvXCSafJZrs4vQcbzbjxDyAsvEAkbY81JtKLDB05AVgmWKZEpos4gNdLkEzRlRLnjha1IUrBmBrG1DCmhjAN4MVq-NmihsbfBr5nxFeDuPR1-2A8OTadJhkvNFGinIm9kq7QHKhVCFqhVVmZIgbwjORlRkXVzufr8diMJoYIwoEh_qTSTATwdClOQ_rEhyTY-PHs3HB_c9o-UqsA7i_Eu1oPfQ-JTisZQLYm-LUFr79pqm9tzW6VcfPDPICXqy3ybywe_i9oj2CLbru4t8ewMZ3M_BNylKa2RxTh4FOv_c3Qa9WhB5vDw887X38BefIT2A |
| linkProvider | Scholars Portal |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED-NTgJe-P4IXwoIgYRI5ySuEz-OiWkgdeKBSuPJOscOdE3TqrRC5a_nLkmrVQO0p3w5kXM-x_fL_e4O4HWZ5lnu8pJp5SKSDn2kldMRplyssBgkMuN45-GpOhnJz2eDsz3YlJJjVuXkfDxtfPireTVDd8DHNJhxHqXJoD935TXYVwOyvHuwPzr9cviNMRVZERFBc3YoN8k1lZJ5m1KTQL1snsE8rryfclHsC0tQk6mfFpZ6Uf7NyLzMlbyxque4_oVVdWEhOr4Nw004T8s_mfRXS9svfl_O7nild7wDtzqLNDxsVegu7Pn6Hlwfdj73-_DuyFcVk1XDMceSdBFb63Bchxs2Yjhd-2o2xQcwOv749egk6iosRAUBlWXkrYoxthgrFNZbp1EJ53WSiNJiKS0Zj55sRCyt9hJdnFltUy-cdJrWeRenD6FXz2r_GMLCC0T6QsQaE-lFho4MBywTLFMC4EUcwPuN0E3RpR_nKhiVIRjCY2RYBoZlYEgGAbzZNp-3eTf-1fADj-C2EafLbk6QdE03-4wXmmBUzj8DlHSFZnJXIaiHVmVlihjAKxp_MynGzf28_T4zk4UhUPHJEOZSaSYCeLlRD0NzkB0rWPvZ6qfhmuiCeqZVAI9addn2h76hBMGVDCDbUaSdDu9eqcc_mjzfKuOCiXkAb7cq939ZPLlyy6dwk3Y7stwz6C0XK_-crKulfdFNqj9agiJq |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cellular+immunotherapy+in+multiple+myeloma&rft.jtitle=The+Korean+journal+of+internal+medicine&rft.au=Vo%2C+Manh-Cuong&rft.au=Lakshmi%2C+Thangaraj+Jaya&rft.au=Jung%2C+Sung-Hoon&rft.au=Cho%2C+Duck&rft.date=2019-09-01&rft.issn=1226-3303&rft.eissn=2005-6648&rft.volume=34&rft.issue=5&rft.spage=954&rft.epage=965&rft_id=info:doi/10.3904%2Fkjim.2018.325&rft.externalDBID=n%2Fa&rft.externalDocID=10_3904_kjim_2018_325 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1226-3303&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1226-3303&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1226-3303&client=summon |